Could an MDR1 Mutation Make Ivermectin Dangerous in Humans? What the Science Actually Says

By Editorial Team May 20, 2026

Introduction

Claims about ivermectin and “MDR1 mutations” have exploded online in recent years. Some posts (X.com) warn that a mutation in the MDR1 gene can make ivermectin instantly toxic or even lethal in humans.

But how accurate is this claim?

The answer is more nuanced. While certain genetic variants involving the MDR1/ABCB1 transporter may increase the risk of ivermectin-related neurotoxicity, the evidence does not support the idea that all humans with an MDR1 mutation will experience fatal reactions at normal doses.

In this evidence-based review, we examine:

what the MDR1 gene actually does,
why ivermectin toxicity occurs,
how humans differ from dogs with MDR1 mutations,
the role of drug interactions,
and what current research says about real-world risk.

What Is the MDR1 Gene?

The MDR1 gene, also known as ABCB1, encodes a transporter protein called P-glycoprotein (P-gp).

P-gp acts like a biological “pump” that helps remove drugs and toxins from sensitive tissues, especially:

the brain,
intestines,
liver,
kidneys,
and placenta.

One of its most important functions is protecting the blood–brain barrier.

Why This Matters for Ivermectin

Normally, ivermectin has limited penetration into the central nervous system because P-gp pumps it back out of the brain.

This is one reason why ivermectin has historically shown a relatively wide therapeutic window in humans when used appropriately.

However, if P-gp function is impaired:

more ivermectin may enter the brain,
increasing the risk of neurotoxicity.

What Happens When Too Much Ivermectin Reaches the Brain?

Potential neurological symptoms may include:

dizziness,
confusion,
tremors,
ataxia,
blurred vision,
seizures,
encephalopathy,
coma.

Severe toxicity is uncommon but has been documented, particularly after:

massive overdoses,
veterinary formulations,
counterfeit products,
or dangerous drug interactions.

The Origin of the “MDR1 Mutation” Warning

The warning largely comes from veterinary medicine.

Certain dog breeds — especially collies and related herding breeds — may carry a severe loss-of-function MDR1 mutation that dramatically reduces P-gp activity.

In these dogs, ivermectin can cross the blood–brain barrier in dangerously high amounts, causing:

profound neurotoxicity,
seizures,
coma,
and death.

This phenomenon is well established in veterinary pharmacology.

Humans Are Different From MDR1-Mutant Dogs

Humans can also carry ABCB1 genetic polymorphisms, but the situation is very different.

Key Difference

In dogs:

the mutation can nearly abolish transporter function.

In humans:

most ABCB1 variants only modestly alter transporter efficiency.

Current evidence does not show that common human ABCB1 variants create the same extreme sensitivity seen in MDR1-mutant dogs.

This is a critical distinction often lost in social media discussions.

The Landmark 2020 NEJM Case Report

One of the most important human reports was published in the New England Journal of Medicine in 2020.

The paper described:

a 13-year-old boy,
who received a single oral ivermectin dose of 230 mcg/kg as prophylaxis for scabies,
and subsequently developed:
- coma,
- ataxia,
- diplopia,
- and pyramidal neurological signs.

A genetic workup later revealed that the boy carried:

compound heterozygous nonsense mutations in ABCB1, the gene encoding P-glycoprotein.

The authors concluded that severe loss-of-function ABCB1 mutations likely allowed unusually high ivermectin penetration into the brain.

Importantly:

the patient recovered within approximately 48 hours,
and the paper did not conclude that ivermectin is universally lethal in people with MDR1-related variants.

This case is scientifically significant because it provides direct evidence that profound P-glycoprotein deficiency can dramatically increase ivermectin neurotoxicity risk in humans.

However, it should not be generalized to all ABCB1 polymorphisms.

Can Human ABCB1 Variants Increase Ivermectin Risk?

Possibly — but usually modestly.

Researchers have investigated whether certain ABCB1 polymorphisms may:

increase ivermectin blood levels,
alter drug clearance,
or enhance brain penetration.

Some studies suggest mild pharmacokinetic differences, but:

clinically severe neurotoxicity remains rare,
and evidence for predictable lethal reactions is weak.

The overall scientific consensus is that genetics alone is usually not the primary driver of toxicity.

The Bigger Risk: Drug Interactions

In clinical practice, drug interactions may be more important than genetics alone.

Several medications inhibit P-glycoprotein activity and could theoretically increase ivermectin exposure in the brain.

Examples include:

Verapamil
Ketoconazole
Clarithromycin
Cyclosporine

Additional concerns may involve:

HIV protease inhibitors,
certain antidepressants,
and grapefruit-related CYP3A4/P-gp interactions.

Combining multiple P-gp inhibitors with high-dose ivermectin could theoretically elevate neurotoxicity risk.

Other Factors That May Increase Toxicity Risk

1. High-Dose Ivermectin Use

Many toxicity cases involve:

doses far above approved ranges,
repeated self-administration,
or veterinary products intended for large animals.

2. Liver Dysfunction

Because ivermectin is metabolized in the liver, impaired hepatic function may alter drug clearance.

3. Blood–Brain Barrier Damage

Conditions that disrupt the blood–brain barrier may increase CNS penetration:

severe infections,
meningitis,
traumatic brain injury,
sepsis,
neuroinflammation.

Has Ivermectin Caused Human Deaths?

Yes — but fatalities are uncommon.

Most reported deaths have involved:

extreme overdoses,
polypharmacy,
counterfeit or veterinary formulations,
or severe intoxication.

Importantly, millions of human doses have been administered globally for conditions such as:

Onchocerciasis
Strongyloidiasis
Scabies

without widespread evidence of genetically driven fatal neurotoxicity.

What Does the Current Evidence Suggest?

The current literature suggests:

Supported by Evidence

ABCB1 variants may modestly influence ivermectin pharmacokinetics.
P-glycoprotein plays a major role in CNS protection.
Drug interactions can increase toxicity risk.
Very high doses increase danger.

Not Supported by Evidence

“Any MDR1 mutation makes ivermectin lethal.”
“Normal ivermectin doses are universally dangerous in mutation carriers.”
“Human MDR1 mutations behave exactly like collie dog mutations.”

Ivermectin Safety and Side Effects

Ivermectin is a key anti-parasitic for the control of neglected tropical diseases. The main indications for population-level control with ivermectin through mass drug administration (MDA) are onchocerciasis and lymphatic filariasis in developing countries. With over 30 years of ample use and over 300 million people using it annually, ivermectin is, through its use in MDA campaigns, among the most relevant public health interventions in the developing world. (Oxford Academic)

Possible side effects could be that you get a cut that will not stop bleeding, or maybe dizziness, altered vision, etc. So there needs to be some consideration and thought given to doses. Ivermectin is a relatively safe drug, but it’s still a DRUG and safety is #1 consideration. There are 105 contraindications, see drugs.com.

Ivermectin has been linked to liver side effects such as elevated ALT and/or AST, elevated liver enzymes, elevated bilirubin, and hepatitis. The drug should be accompanied by adequate monitoring of liver enzymes, especially in patients with previous liver disease such as cirrhosis.

Safety and pharmacokinetics (PK) of the antiparasitic drug ivermectin, administered in higher and/or more frequent doses than currently approved for human use, were evaluated in a double-blind, placebo-controlled, dose escalation study. Subjects (n = 68) were assigned to one of four panels (3:1, ivermectin/placebo): 30 or 60 mg (three times a week) or 90 or 120 mg (single dose). The 30 mg panel (range: 34 7-594 microg/kg) also received a single dose with food after a 1-week washout. Safety assessments addressed both known ivermectin CNS effects and general toxicity.

A 2020 systematic review, including a meta-analysis, has shown that Adverse Events following single-dose treatment with up to 800 μg/kg of ivermectin occur without significant differences of frequency or intensity to those at regular currently approved doses. Ocular AEs, despite being transient, are of concern in onchocerciasis patients, requiring caution and further studies if ivermectin is used at high doses for that indication.

The primary safety endpoint was mydriasis, accurately quantitated by pupillometry. Ivermectin was generally well tolerated, with no indication of associated CNS toxicity for doses up to 10 times the highest FDA-approved dose of 0.2 mg/kg. All dose regimens had a mydriatic effect (A "mydriatic" is a substance or agent that causes the pupil of the eye to dilate) similar to placebo. (Guzzo et al 2002)

Adverse experiences were similar between ivermectin and placebo and did not increase with dose. Following single doses of 30 to 120 mg, AUC and Cmax were generally dose proportional, with t(max) approximately 4 hours and t1/2 approximately 18 hours. The geometric mean AUC of 30 mg ivermectin was 2.6 times higher when administered with food. This study demonstrated that ivermectin is generally well tolerated at these higher doses and more frequent regimens. (Guzzo et al 2002)

A dose between 0.05 and 0.40 mg/kg does not cause unwanted effects and risk to human life; doses between 6.6 and 8.6 mg/kg are toxic, causing vomiting, blurred vision, mydriasis, ataxia, tremor, and coma, and finally, lethal doses are of 24 mg/kg. (Yuliana et al 2023)

According to Ivermectin's safety data sheet (Merck):

LD50 (Monkey): > 24 mg/kg
Target Organs: Central nervous system
Symptoms: Vomiting, Dilatation of the pupil
Remarks: No mortality observed at this dose.

Ivermectin vs Ivomec?
Human ivermectin is a tightly regulated, pharmaceutical-grade medication with precise, weight-based dosing and safety standards, whereas Ivomec is a veterinary formulation that may contain solvents or additives not approved for human use and is often produced at much higher concentrations. Because of these critical differences in purity, formulation, and dosage, human and animal ivermectin products are not interchangeable, and health authorities consistently warn against using veterinary versions in people due to the risk of overdose, toxicity, and unpredictable side effects.

Related: Ivermectin Dosage Guide for Humans (2025)

Clinical Bottom Line

The claim that “MDR1 mutations make ivermectin lethal in humans” is an oversimplification not supported by current evidence.

However, caution may still be warranted in individuals with:

unusual drug sensitivities,
major liver dysfunction,
blood–brain barrier disorders,
or concurrent use of strong P-glycoprotein inhibitors.

As with many medications, toxicity risk depends on:

dose,
genetics,
co-medications,
formulation quality,
and overall health status.

The most evidence-based approach is individualized medical supervision rather than fear-driven generalizations.

Frequently Asked Questions (FAQ)

Is ivermectin safe in humans?

When prescribed appropriately for approved indications, ivermectin has been widely used in humans for decades.

Can genetics affect ivermectin response?

Possibly. ABCB1 variants may modestly alter drug transport, but severe reactions remain uncommon.

Why are dogs more sensitive?

Certain dog breeds may carry severe MDR1 loss-of-function mutations that dramatically impair blood–brain barrier protection.

Are veterinary ivermectin products dangerous?

Yes. Veterinary formulations may contain much higher concentrations and should never be used without medical supervision.

Should people get genetic testing before ivermectin?

Routine ABCB1 testing before standard ivermectin use is not currently recommended in most clinical settings.

References

Baudou E, Lespine A, Durrieu G, et al. Serious Ivermectin Toxicity and Human ABCB1 Nonsense Mutations (NEJM, 2020). New England Journal of Medicine. 2020;383(8):787–789.